Eli Lilly
Lilly is winning the obesity market on volume. Q3 revenue grew 39% to $24.4B as volumes rose 53%, more than offsetting a 15% fall in prices. Its tirzepatide drugs (Mounjaro and Zepbound) now make up about 65% of revenue. Novo Nordisk still leads in pills: its Wegovy pill sold about $810M vs $184M for Lilly’s Foundayo. The open questions are how fast prices keep falling, whether Foundayo catches up, and when the next drug, retatrutide, arrives. Lilly trades at about 31x forward P/E, with a market value about 6x Novo’s.

The first slides, as they appear in the reader.




No PDF to download or forward.
How to read it.
Starter
Not included
Qubo Research is for subscribers, from Pulse.
Pulse · Edge
1 or 5 reports a month
1 with Pulse, 5 with Edge, plus previews and flash notes.
Apex
Library included
Every report, every edition and the archives. 5 custom reports a month.
Editions:Nov 2026Follow the series in the Terminal to get the next one.
Read it next to the live LLY chart.
Open the report in the Terminal: price, news and why it moves, on the same screen.
General research, the same for every reader: it does not take anyone’s situation into account and does not recommend buying, selling or holding any asset. No price targets. May contain errors.